Floatz logo

Neratinib

KRAS Gene Mutation

M.D. Anderson Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the KRAS Gene Mutation cohort.

Asset / SponsorPhaseRating
gsk1120212
Memorial Sloan Kettering Cancer Center
Phase 2BB
Regorafenib
Stanford University
Phase 2B
5-azacytidine
Stanford University
Phase 2B
METHOTREXATE
Stanford University
Phase 2B
Palbociclib
Calithera Biosciences, Inc
Phase 1/2B

View all 30 →

Same molecule, other indications

Neratinib is also rated in:

breast carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Metastatic Breast CarcinomaDormant
B
Indicative ·
62 / 100
View asset →
breast cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →